GC
ABCL icon

Guggenheim Capital’s AbCellera Biologics ABCL Stock Holding History

Guggenheim Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,362
Closed -$26.9K – 1680
2024
Q3 		$26.9K Sell
10,362
-922
-8% -$2.56K ﹤0.01% 1855
2024
Q2 		$33.4K Sell
11,284
-260
-2% -$984 ﹤0.01% 1852
2024
Q1 		$52.3K Sell
11,544
-194
-2% -$990 ﹤0.01% 1859
2023
Q4 		$67K Sell
11,738
-457
-4% -$2.12K ﹤0.01% 1861
2023
Q3 		$56.1K Buy
12,195
+283
+2% +$1.72K ﹤0.01% 1825
2023
Q2 		$77K Sell
11,912
-3,049
-20% -$20.8K ﹤0.01% 1846
2023
Q1 		$113K Buy
14,961
+4,337
+41% +$39.4K ﹤0.01% 1869
2022
Q4 		$108K Buy
+10,624
New +$123K ﹤0.01% 1866

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Guggenheim Capital's ABCL Position: Q4 2024 in Review

Guggenheim Capital sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 10,362 shares — an estimated $26.9K sold.

Guggenheim Capital first reported a position in ABCL in Q4 2022 and held it in 8 quarters. The position peaked at $113K in Q1 2023. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • Guggenheim Capital reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • Guggenheim Capital sold 10,362 AbCellera Biologics shares in Q4 2024, an estimated $26.9K.
  • Guggenheim Capital first reported a position in AbCellera Biologics in Q4 2022 and held it in 8 quarters.
  • Guggenheim Capital's AbCellera Biologics position peaked at $113K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on Guggenheim Capital's 13F filing for Q4 2024, filed 13 Feb 2025.